Circulating nitric oxide levels in galactorrheic, hyperprolactinemic, amenorrheic women

Fertility and Sterility

Volumn 68, Issue 3, 1997, Pages 454-459

  Shaarawy, Mohamed ^a   El Sharkawy, Sherif ^a   Nafei, Sami ^a   Younis, Ashraf ^a   Abul Nasr, Ahmed ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Amenorrhea; Cardiovascular disorders; Estrogen deficiency; Hyperprolactinemia; Nitric oxide

Indexed keywords

BROMOCRIPTINE; NITRIC OXIDE; PROLACTIN;

ADULT; AMENORRHEA; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; ORAL DRUG ADMINISTRATION; OVARY FUNCTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0343247779     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)00225-2     Document Type: Article

References (25)

1. Franks S, Murray MAF, Jecquier AM, Steele SJ, Nabarro JDN, Jacobs HS. Incidence and significance of hyperprolactinemia in women with amenorrhea. Clin Endocrinol (Oxf) 1975;4:597-602.
2. Lachelin GDL, Abu-Fadil S, Yen SSC. Functional delineation of hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1977;44:1163-8.
3. Luscher TF, Dabey RK. Endothelium and platelet-derived vasoactive substances: role in the regulation of vascular tone and growth. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1994:609-30.
4. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866-79.
5. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-55.
6. Dubey RK. Vasodilator-derived nitric oxide inhibits angiotensin-II and fetal calf serum-induced growth of arteriolar smooth muscle cells. J Pharmacol Exp Ther 1994;269:402-8.
7. Roselli M, Imthurn B, Macas E, Keller PJ, Dubey RK. Circulating nitrite/nitrate levels increase with follicular development: indirect evidence for estradiol mediated NO-release. Biochem Biophys Res Commun 1994;202:1543-52.
8. Hibbs JB, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992;89:867-77.
9. Roselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β estradiol and norethisterone acetate. A two year follow up study. Hypertension 1995;25:848-53.
10. Kharitonov SA, Logan-Sinclair RB, Busset CM, Shinebourne EA. Peak expiratory nitric oxide differences in men and women; relation to the menstrual cycle. Br Heart J 1994;72:243-5.
11. Seki K, Kato K, Shima K. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma. J Clin Endocrinol Metab 1986;63:1225-31.
12. Dorrington J, Gore-Langton RE. Prolactin inhibits estrogen synthesis in the ovary. Nature 1981;290:600-8.
13. Kauppila A, Leinonen P, Vikbo R, Ylostalo P. Metoclopramide-induced hyperprolactinemia impairs ovarian follicle maturation and corpus luteum function in women. J Clin Endocrinol Metab 1982;54:955-62.
14. Brosnihan KB, Moriguchi A, Nakamoto H, Dean RH, Ganten D, Ferrario CM. Estrogen augments the contribution of nitric oxide to blood pressure regulation in transgenic hypertensive rats expressing the mouse Ren-2 gene. Am J Hypertens 1994;7:576-82.
15. Okamura H, Yokosuka M, McEwen BS, Hyashi S. Colonization of NADPH-diaphorase and estrogen receptor immuno-reactivity in the rat ventromedial hypothalamic nucleus: stimulatory effect of estrogen on NADPH-diaphorase activity. Endocrinology 1994;135:1705-8.
16. Rozenberg S, Liebens I, Vandromme J, Hotimsky A, Van-Rijsselberge M. Cardiovascular protection by estrogen: a hemodynamic mechanism. Int J Fertil Menopausal Stud 1994;39:36-42.
17. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A 1992;89:11259-63.
18. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-7.
19. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
20. Van-Buren GA, Yang DS, Clark KE. Estrogen-induced uterine vasodilation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide-synthesis. Am J Obstet Gynecol 1992;167:828-33.
21. Henry PD, Cabello OA. Vasoprotection and antihypertensive therapy. Curr Opin Nephrol Hypertens 1995;4:197-200.
22. Mendlsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-26.
23. Ellman C, Corbett JA, Misko T, McDaniel M, Beckerman KP. Nitric oxide mediates interleukin-1-induced cellular cytotoxicity in the rat ovary. A potential role for nitric oxide in the ovulatory process. J Clin Invest 1993;92:3053-6.
24. Van-Voorrhis BJ, Dunn MS, Snyder GD, Weiner CP. Nitric oxide: an autocrine regulator of human granulosa-luteal cell steroidogenesis. Endocrinology 1994;135:1799-806.
25. Ben-Shlomo I, Adashi EY, Payne DW. The morphogenic/cytotoxic and prostaglandin-stimulating activities of interleukin-1β in the rat ovary are nitric oxide dependent. J Clin Invest 1994;94:1463-9.